Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2017 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study.
Keizman D, Frenkel M, Peer A, Kushnir I, Rosenbaum E, Sarid D, Leibovitch I, Mano R, Yossepowitch O, Margel D, Wolf I, Geva R, Dresler H, Rouvinov K, Rapoport N, Eliaz I. Keizman D, et al. Nutrients. 2021 Nov 28;13(12):4295. doi: 10.3390/nu13124295. Nutrients. 2021. PMID: 34959847 Free PMC article. Clinical Trial.
Optimal therapy of biochemically relapsed prostate cancer (BRPC) after local treatment is elusive. An established modified citrus pectin (PectaSol(), P-MCP), a dietary polysaccharide, is an established antagonist of galectin-3, a carbohydrate-binding protein …
Optimal therapy of biochemically relapsed prostate cancer (BRPC) after local treatment is elusive. An established modified citrus
Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.
Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Guess BW, et al. Prostate Cancer Prostatic Dis. 2003;6(4):301-4. doi: 10.1038/sj.pcan.4500679. Prostate Cancer Prostatic Dis. 2003. PMID: 14663471 Clinical Trial.
This trial investigated the tolerability and effect of modified citrus pectin (Pecta-Sol) in 13 men with prostate cancer and biochemical prostate-specific antigen (PSA) failure after localized treatment, that is, radical prostatectomy, radiation, or cr …
This trial investigated the tolerability and effect of modified citrus pectin (Pecta-Sol) in 13 men with prostate cance …
Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study.
Ried K, Eng P, Sali A. Ried K, et al. Asian Pac J Cancer Prev. 2017 Aug 27;18(8):2275-2285. doi: 10.22034/APJCP.2017.18.8.2275. Asian Pac J Cancer Prev. 2017. PMID: 28843267 Free PMC article.
Follow-up tests including scans, scheduled within 1-10 months of positive CTC tests, found early cancerous lesions in 20% of screened patients. In 50% of male patients with CTC and normal PSA (prostate-specific-antigen) levels, PSMA-PET scans revealed increased uptake in t …
Follow-up tests including scans, scheduled within 1-10 months of positive CTC tests, found early cancerous lesions in 20% of screened patien …